ID: ALA4282693

Max Phase: Preclinical

Molecular Formula: C19H13Cl2F2NO2S

Molecular Weight: 428.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1c(F)cccc1F)c1sccc1OCc1ccc(Cl)cc1Cl

Standard InChI:  InChI=1S/C19H13Cl2F2NO2S/c20-12-5-4-11(14(21)8-12)10-26-17-6-7-27-18(17)19(25)24-9-13-15(22)2-1-3-16(13)23/h1-8H,9-10H2,(H,24,25)

Standard InChI Key:  KVMCBBWABOUSJA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 428.29

Molecular Weight (Monoisotopic): 427.0012

AlogP: 5.84

#Rotatable Bonds: 6

Polar Surface Area: 38.33

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.78

CX Basic pKa:

CX LogP: 5.75

CX LogD: 5.75

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.54

Np Likeness Score: -1.96

References

1. Lim JW, Kim SK, Choi SY, Kim DH, Gadhe CG, Lee HN, Kim HJ, Kim J, Cho SJ, Hwang H, Seong J, Jeong KS, Lee JY, Lim SM, Lee JW, Pae AN..  (2018)  Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.,  157  [PMID:30103190] [10.1016/j.ejmech.2018.07.071]

2. Whitfield H, Hemmings AM, Mills SJ, Baker K, White G, Rushworth S, Riley AM, Potter BVL, Brearley CA..  (2021)  Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.,  64  (7.0): [PMID:33724834] [10.1021/acs.jmedchem.0c01944]

Source

Source(1):

• Scientific Literature